期刊文献+

溃疡性结肠炎频发的危险因素Logistic回归分析 被引量:10

Logistic regression analysis of risk factors for frequent incidence of ulcerative colitis
下载PDF
导出
摘要 目的分析影响溃疡性结肠炎(UC)频发的危险因素。方法收集2015年1月至2018年6月在我院确诊并住院治疗的慢性复发型UC患者119例的临床资料,根据复发次数将112例(除去7例为持续型)UC患者分为频发组(n=61)与偶发组(n=51)。采用单因素及多因素Logistic回归分析对影响UC频发的因素进行分析。结果单因素分析结果显示,两组患者的用药依从性、SAS评分、SDS评分、疾病严重程度、内镜下评分比较,差异有统计学意义(P<0.05);多因素Logistic回归分析结果显示,用药依从性、SAS评分、SDS评分、重度病情及内镜下评分是影响慢性复发型UC频发的独立危险因素(P<0.05)。结论 UC患者频发与多种因素相关,临床应加强依从性管理,改善患者心理状况,延缓疾病进展,尽可能达到内镜下黏膜愈合标准以减少复发次数,提高患者生存质量。 Objective To analyze the risk factors affecting the frequency of ulcerative colitis(UC). Methods The clinical data of 119 patients with chronic recurrent UC diagnosed and hospitalized in our hospital from January 2015 to June 2018 were collected. A total of 112 patients(excluding 7 patients with persistent UC) were divided into frequent group(n=61)and accidental group(n =51) according to the numbers of recurrence. Univariate and multivariate Logistic regression analysis were used to analyze the risk factors affecting the frequency of UC. Results The results of univariate analysis showed that there were significant differences in medication compliance, SAS scores, SDS scores, disease severity and endoscopy scores between the two groups(P <0.05). The results of multivariate Logistic regression analysis showed that medication compliance, SAS scores, SDS scores, severe disease and endoscopy score were the independent risk factors affecting the frequent incidence of chronic recurrent UC(P<0.05). Conclusion The frequent incidence of UC is related to many factors. It is necessary to strengthen the management of drug compliance of patients, improve the psychological status of patients, delay the progress of the disease and reach the criteria of endoscopic mucosal healing as far as possible, so as to reduce the numbers of recurrence and improve the quality of life of patients.
作者 朱林林 王巧民 陈思 江秋霞 李鸣涛 李浩 ZHU Lin-lin;WANG Qiao-min;CHEN Si;JIANG Qiu-xia;LI Ming-tao;LI Hao(Gastroenterology Department, Anhui Provincal Hospital Affilated to Anhui Medical University, Hefei 230001, China)
出处 《临床医学研究与实践》 2019年第11期80-82,共3页 Clinical Research and Practice
关键词 溃疡性结肠炎 频发 偶发 ulcerative colitis frequent accidental
  • 相关文献

参考文献4

二级参考文献103

  • 1柳婧,高翔,陈烨,梅俏,朱良如,韩英,田丰,张虎,张晓岚,缪应雷,于晓峰,施华秀,王承党,刘玉兰,王晓艳,李学锋,钱家鸣,胡品津,曹倩.中国炎症性肠病患者深静脉血栓情况调查:一项全国多中心回顾性研究[J].中华炎性肠病杂志(中英文),2017,1(1):24-28. 被引量:26
  • 2陈白莉,钱家鸣,吴开春,盛剑秋,许建明,冉志华,袁耀宗,王化虹,陈志芬,李兆申,唐承薇,侯晓华,侯妍妍,陈旻湖,胡品津.英夫利西治疗活动性溃疡性结肠炎疗效与安全性的临床研究[J].中华炎性肠病杂志(中英文),2017,1(1):20-23. 被引量:15
  • 3Elif Yorulmaz,Aslihan Sezgin,Gupse Adali,Hatice Yorulmaz,Hilmi Ciftci.Prolonged QT dispersion in inflammatory bowel disease[J].World Journal of Gastroenterology,2013,19(1):65-71. 被引量:8
  • 4李亚红,韩英,吴开春.炎症性肠病危险因素的流行病学调查研究[J].胃肠病学和肝病学杂志,2006,15(2):161-162. 被引量:19
  • 5Schabert VF, Watson C, Joseph GJ, et al. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population[J]. J Manag Care Pharm, 2013, 19(8): 621-630.
  • 6Xu C, Wang X, Mu R, et al. Societal costs of rheumatoid arthritis in China: a hospital-based cross-sectional study[J]. Arthritis Care Res (Hoboken), 2014, 66(4): 523-531.
  • 7Van der Heijde D, Klareskog L, Landewe R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis[J]. Arthritis Rheum, 2007, 56 ( 12): 3928- 3939.
  • 8Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanercept- methotrexate therapy versus monotherapy in early rheumatoidarthritis: a two-year, double-blind, randomized study[J]. Arthritis Rheum, 2010, 62(3): 674-682.
  • 9Braun J, van der Horst-Bruinsma IE, Huang F, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial[J]. Arthritis Rheum, 2011, 63(6): 1543-1551.
  • 10Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etan- ercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry[J]. Arthritis Rheum, 2010, 62( 1 ) : 22-32.

共引文献653

同被引文献103

引证文献10

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部